Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1106-2023Class II

cobas Influenza A/B & RSV UC (Utility Channel) Qualitative nucleic acid test for use on the cobas 6800/8800...

Roche Molecular Systems Inc / initiated 2022-12-21 / Open, Classified / root cause: design

Roche Molecular Systems, Inc. began a recall of cobas Influenza A/B & RSV UC (Utility Channel) Qualitative nucleic acid test for use on the cobas 6800/8800 Systems; Material number 09233962190 on . FDA classified it as Class II and gives the reason as "The firm received customer complaints regarding false negative Influenza A (Flu A) results and late Flu A Target Ct values. A false negative influenza A result may lead to additional testing, psychological distress, and...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as design.

Recall record

Recall number
Z-1106-2023
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Roche Molecular Systems Inc
Product
cobas Influenza A/B & RSV UC (Utility Channel) Qualitative nucleic acid test for use on the cobas 6800/8800 Systems; Material number 09233962190
Product code
QLT Covid-19 Multi-Analyte Respiratory Panel Nucleic Acid Devices
Reason for recall
The firm received customer complaints regarding false negative Influenza A (Flu A) results and late Flu A Target Ct values. A false negative influenza A result may lead to additional testing, psychological distress, and delays to targeted therapy for influenza as well as true diagnosis.
Root cause tag
design
FDA root cause
Device Design
Action
On December 22, 2022, Roche posted the Urgent Medical Device Correction (UMDC) to its website (dialog.roche.com). On December 27, 2022, the firm also sent UMDC letters to affected customers. Consignees were instructed to monitor for negative influenza A results that are inconsistent with clinical presentation and/or other clinical and epidemiological information. Authorized or licensed Influenza NAATs are available for confirmation if clinically indicated for at-risk patients. Additionally, consignees are reminded to review the tests Instructions for Use, specifically the Intended Use Statements and Procedural Limitations sections, which provide guidance on how negative results should be utilized and mutations within the target regions of the tests can impact detection, respectively. Please contact the Roche Support Network Customer Support Center, 24 hours a day, seven days a week at 1-800-428-2336 if you have questions about this recall
Quantity in commerce
727 kits OUS only
Distribution
Domestic distribution nationwide. Foreign distribution worldwide.
Product codes and lots
UDI-DI 00875197006773 All in-date lots

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1106-2023
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1104-2023Class IIOngoingVoluntary: Firm initiated
Z-1105-2023Class IIOngoingVoluntary: Firm initiated
Z-1106-2023Class IIOngoingVoluntary: Firm initiated